Methylation pattern analysis in prostate cancer tissue

Identification of biomarkers using an MS-MLPA approach

Giorgia Gurioli, Samanta Salvi, Filippo Martignano, Flavia Foca, Roberta Gunelli, Matteo Costantini, Giacomo Cicchetti, Ugo Giorgi, Persio Dello Sbarba, Daniele Calistri, Valentina Casadio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Epigenetic silencing mediated by CpG island methylation is a common feature of many cancers. Characterizing aberrant DNA methylation changes associated with prostate carcinogenesis could potentially identify a tumour-specific methylation pattern, facilitating the early diagnosis of prostate cancer. The objective of the study was to assess the methylation status of 40 tumour suppressor genes in prostate cancer and healthy prostatic tissues. Methods: We used methylation specific-multiplex ligation probe amplification (MS-MLPA) assay in two independent case series (training and validation set). The training set comprised samples of prostate cancer tissue (n = 40), healthy prostatic tissue adjacent to the tumor (n = 26), and healthy non prostatic tissue (n = 23), for a total of 89 DNA samples; the validation set was composed of 40 prostate cancer tissue samples and their adjacent healthy prostatic tissue, for a total of 80 DNA samples. Methylation specific-polymerase chain reaction (MSP) was used to confirm the results obtained in the validation set. Results: We identified five highly methylated genes in prostate cancer: GSTP1, RARB, RASSF1, SCGB3A1, CCND2 (P < 0.0001), with an area under the ROC curve varying between 0.89 (95 % CI 0.82-0.97) and 0.95 (95 % CI 0.90-1.00). Diagnostic accuracy ranged from 80 % (95 % CI 70-88) to 90 % (95 % CI 81-96). Moreover, a concordance rate ranging from 83 % (95 % CI 72-90) to 89 % (95 % CI 80-95) was observed between MS-MLPA and MSP. Conclusions: Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 was highly tumour-specific in prostate cancer tissue.

Original languageEnglish
Article number249
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - Aug 30 2016

Fingerprint

Methylation
Biomarkers
Ligation
Amplification
Prostatic Neoplasms
Tissue
Tumors
Neoplasms
Genes
CpG Islands
Polymerase chain reaction
DNA
DNA Methylation
Tumor Suppressor Genes
Early Detection of Cancer
Epigenomics
ROC Curve
Area Under Curve
Prostate
Assays

Keywords

  • Early diagnosis
  • Methylation pattern
  • MS-MLPA
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Methylation pattern analysis in prostate cancer tissue : Identification of biomarkers using an MS-MLPA approach. / Gurioli, Giorgia; Salvi, Samanta; Martignano, Filippo; Foca, Flavia; Gunelli, Roberta; Costantini, Matteo; Cicchetti, Giacomo; Giorgi, Ugo; Sbarba, Persio Dello; Calistri, Daniele; Casadio, Valentina.

In: Journal of Translational Medicine, Vol. 14, No. 1, 249, 30.08.2016.

Research output: Contribution to journalArticle

@article{dd3ccf50283c4feeae879b1a1293a76c,
title = "Methylation pattern analysis in prostate cancer tissue: Identification of biomarkers using an MS-MLPA approach",
abstract = "Background: Epigenetic silencing mediated by CpG island methylation is a common feature of many cancers. Characterizing aberrant DNA methylation changes associated with prostate carcinogenesis could potentially identify a tumour-specific methylation pattern, facilitating the early diagnosis of prostate cancer. The objective of the study was to assess the methylation status of 40 tumour suppressor genes in prostate cancer and healthy prostatic tissues. Methods: We used methylation specific-multiplex ligation probe amplification (MS-MLPA) assay in two independent case series (training and validation set). The training set comprised samples of prostate cancer tissue (n = 40), healthy prostatic tissue adjacent to the tumor (n = 26), and healthy non prostatic tissue (n = 23), for a total of 89 DNA samples; the validation set was composed of 40 prostate cancer tissue samples and their adjacent healthy prostatic tissue, for a total of 80 DNA samples. Methylation specific-polymerase chain reaction (MSP) was used to confirm the results obtained in the validation set. Results: We identified five highly methylated genes in prostate cancer: GSTP1, RARB, RASSF1, SCGB3A1, CCND2 (P < 0.0001), with an area under the ROC curve varying between 0.89 (95 {\%} CI 0.82-0.97) and 0.95 (95 {\%} CI 0.90-1.00). Diagnostic accuracy ranged from 80 {\%} (95 {\%} CI 70-88) to 90 {\%} (95 {\%} CI 81-96). Moreover, a concordance rate ranging from 83 {\%} (95 {\%} CI 72-90) to 89 {\%} (95 {\%} CI 80-95) was observed between MS-MLPA and MSP. Conclusions: Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 was highly tumour-specific in prostate cancer tissue.",
keywords = "Early diagnosis, Methylation pattern, MS-MLPA, Prostate cancer",
author = "Giorgia Gurioli and Samanta Salvi and Filippo Martignano and Flavia Foca and Roberta Gunelli and Matteo Costantini and Giacomo Cicchetti and Ugo Giorgi and Sbarba, {Persio Dello} and Daniele Calistri and Valentina Casadio",
year = "2016",
month = "8",
day = "30",
doi = "10.1186/s12967-016-1014-6",
language = "English",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Methylation pattern analysis in prostate cancer tissue

T2 - Identification of biomarkers using an MS-MLPA approach

AU - Gurioli, Giorgia

AU - Salvi, Samanta

AU - Martignano, Filippo

AU - Foca, Flavia

AU - Gunelli, Roberta

AU - Costantini, Matteo

AU - Cicchetti, Giacomo

AU - Giorgi, Ugo

AU - Sbarba, Persio Dello

AU - Calistri, Daniele

AU - Casadio, Valentina

PY - 2016/8/30

Y1 - 2016/8/30

N2 - Background: Epigenetic silencing mediated by CpG island methylation is a common feature of many cancers. Characterizing aberrant DNA methylation changes associated with prostate carcinogenesis could potentially identify a tumour-specific methylation pattern, facilitating the early diagnosis of prostate cancer. The objective of the study was to assess the methylation status of 40 tumour suppressor genes in prostate cancer and healthy prostatic tissues. Methods: We used methylation specific-multiplex ligation probe amplification (MS-MLPA) assay in two independent case series (training and validation set). The training set comprised samples of prostate cancer tissue (n = 40), healthy prostatic tissue adjacent to the tumor (n = 26), and healthy non prostatic tissue (n = 23), for a total of 89 DNA samples; the validation set was composed of 40 prostate cancer tissue samples and their adjacent healthy prostatic tissue, for a total of 80 DNA samples. Methylation specific-polymerase chain reaction (MSP) was used to confirm the results obtained in the validation set. Results: We identified five highly methylated genes in prostate cancer: GSTP1, RARB, RASSF1, SCGB3A1, CCND2 (P < 0.0001), with an area under the ROC curve varying between 0.89 (95 % CI 0.82-0.97) and 0.95 (95 % CI 0.90-1.00). Diagnostic accuracy ranged from 80 % (95 % CI 70-88) to 90 % (95 % CI 81-96). Moreover, a concordance rate ranging from 83 % (95 % CI 72-90) to 89 % (95 % CI 80-95) was observed between MS-MLPA and MSP. Conclusions: Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 was highly tumour-specific in prostate cancer tissue.

AB - Background: Epigenetic silencing mediated by CpG island methylation is a common feature of many cancers. Characterizing aberrant DNA methylation changes associated with prostate carcinogenesis could potentially identify a tumour-specific methylation pattern, facilitating the early diagnosis of prostate cancer. The objective of the study was to assess the methylation status of 40 tumour suppressor genes in prostate cancer and healthy prostatic tissues. Methods: We used methylation specific-multiplex ligation probe amplification (MS-MLPA) assay in two independent case series (training and validation set). The training set comprised samples of prostate cancer tissue (n = 40), healthy prostatic tissue adjacent to the tumor (n = 26), and healthy non prostatic tissue (n = 23), for a total of 89 DNA samples; the validation set was composed of 40 prostate cancer tissue samples and their adjacent healthy prostatic tissue, for a total of 80 DNA samples. Methylation specific-polymerase chain reaction (MSP) was used to confirm the results obtained in the validation set. Results: We identified five highly methylated genes in prostate cancer: GSTP1, RARB, RASSF1, SCGB3A1, CCND2 (P < 0.0001), with an area under the ROC curve varying between 0.89 (95 % CI 0.82-0.97) and 0.95 (95 % CI 0.90-1.00). Diagnostic accuracy ranged from 80 % (95 % CI 70-88) to 90 % (95 % CI 81-96). Moreover, a concordance rate ranging from 83 % (95 % CI 72-90) to 89 % (95 % CI 80-95) was observed between MS-MLPA and MSP. Conclusions: Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 was highly tumour-specific in prostate cancer tissue.

KW - Early diagnosis

KW - Methylation pattern

KW - MS-MLPA

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84984629917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984629917&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-1014-6

DO - 10.1186/s12967-016-1014-6

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 249

ER -